Immatics $110 million follow-on offering
Davis Polk advised Immatics N.V. in connection with its $110 million SEC-registered offering of ordinary shares. The ordinary shares are listed on Nasdaq under the symbol “IMTX.”
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for its pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as its partnerships with global leaders in the pharmaceutical industry. Immatics is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar, counsel John H. Runne and associates David Li and Christian Knoble. Partner Mario J. Verdolini and associate Constance Zhang provided tax advice. Partner David R. Bauer provided intellectual property advice. Associate Ann Herman provided 1940 Act advice. All members of the Davis Polk team are based in the New York office.